Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exact Sciences Cor (EXAS) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,067,380
  • Shares Outstanding, K 108,410
  • Annual Sales, $ 39,440 K
  • Annual Income, $ -157,800 K
  • 36-Month Beta 0.85
  • Price/Sales 26.31
  • Price/Book 5.71

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.05 +45.90%
on 01/03/17
19.39 -1.81%
on 01/12/17
+5.16 (+37.18%)
since 12/13/16
3-Month
13.05 +45.90%
on 01/03/17
20.40 -6.67%
on 10/20/16
+0.50 (+2.70%)
since 10/13/16
52-Week
4.67 +307.71%
on 03/01/16
22.80 -16.49%
on 08/15/16
+12.34 (+184.18%)
since 01/13/16

Most Recent Stories

More News
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees

Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 53,275 shares of common stock to 45 recently...

EXAS Crosses Above Average Analyst Target

In recent trading, shares of EXACT Sciences Corp. have crossed above the average analyst 12-month target price of $19.00, changing hands for $19.07/share.

The Top 100 U.S. In-Vitro Diagnostics Companies

Did you know?

Exact Sciences to report $99 million in revenues, 150 percent growth for 2016

Exact Sciences Corp. (Nasdaq: EXAS) announced today that the company expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, an increase of 142 percent...

Cologuard Earns Positive Review from Blue Cross Blue Shield Association

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Blue Cross Blue Shield Association's (BCBSA) Center for Clinical Effectiveness "Evidence Street" recently released a positive review of Cologuard...

New Strong Buy Stocks for December 29th

New Strong Buy Stocks for December 29th

Exact Sciences (EXAS): Strong Industry, Solid Earnings Estimate Revisions

Exact Sciences (EXAS) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option

Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Humana Inc. agreed to cover Cologuard as an in-network service for its members, effective January 1, 2017. Under...

Technical Reports on Healthcare Stocks -- Exact Sciences, Agilent Technologies, Hill-Rom, and Waters

Today, Stock-Callers.com has issued research reports on: Exact Sciences Corp. (NASDAQ: EXAS), Agilent Technologies Inc. (NYSE: A), Hill-Rom Holdings Inc. (NYSE: HRC), and Waters Corp. (NYSE: WAT). These...

Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Jeff Elliott as chief financial officer. Mr. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in...

See More

Support & Resistance

2nd Resistance Point 19.68
1st Resistance Point 19.36
Last Price 19.04
1st Support Level 18.74
2nd Support Level 18.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.